Brief: Kineta Inc Files For Mixed Shelf Of Up To $200 Mln - SEC Filing
Brief: Kineta Receives Notice Of Termination Of Exclusive Option,License Agreement From Genentech
U.S. STOCKS ON THE MOVE-Tesla, Athenex Inc, Entrada Therapeutics
U.S. STOCKS ON THE MOVE-Pot stocks, Nymox, Zynerba
U.S. STOCKS ON THE MOVE-TFF Pharma, BioRestorative,
U.S. STOCKS ON THE MOVE-Energy firms, Nkarta, Domino's Pizza
Yumanity Therapeutics up on declaring special dividend
Brief: Yumanity Therapeutics Declares Special Dividend In Connection With Proposed Asset Sale To Janssen, Merger With Kineta
Brief: Yumanity Therapeutics Announces Effectiveness Of Registration Statement On Form S-4
Brief: Yumanity Therapeutics To Present Anti-CD27 Agonist Preclinical Program At AACR Conference
Brief: Yumanity Files Registration Statement On Form S-4 For Proposed Asset Sale To Janssen And Merger With Kineta
Brief: Yumanity Therapeutics Reports Second Quarter 2022 Financial Results And Recent Corporate Developments
U.S. STOCKS ON THE MOVE-BGC Partners Inc, Hyatt Hotel Corp, Metlife Inc
U.S. STOCKS ON THE MOVE-Kroger Co, Amarin Corp, Eli Lilly and Co
U.S. STOCKS ON THE MOVE-Amazon.com Inc, Starbucks Corp, Anaplan Inc
U.S. STOCKS ON THE MOVE-Didi Global, Apple Inc, Tesla Inc
Yumanity Therapeutics jumps on sale of lead drug, merger with unit Kineta
Brief: Yumanity Therapeutics To Merge With Kineta In All-Stock Deal
Yumanity Therapeutics Inc reports results for the quarter ended in March - Earnings Summary